Private Investors Diary Portfolio

John Rosier thinks there is a strong case for the UK closing the valuation gap on overseas markets

John Rosier explains how he plans to deal with a gap in his portfolio and why he still likes oil and gas

John Rosier reports on the changes he has made to his portfolio

John Rosier identifies areas of volatility in the portfolio but notes that reducing these holdings would impact returns

John Rosier adopts a new approach to evaluating his portfolio holdings

John Rosier focuses on the art of finding shares that have the potential to rise in value by at least 100 times

Our private investor diarist reflects on his portfolio's performance in June and cautions against being in a position where one stock can do irreparable damage

Worries about a general election prompt John Rosier to make a series of changes to his portfolio

Our private investor diarist has compiled a unique and demanding benchmark for performance comparisons

John Rosier continues to ensure he is well diversified geographically and from a currency perspective during the Brexit process

John Rosier is hoping for great things from one particular holding – energy production company RockRose and its potentially transformational deal

John Rosier takes the plunge with a trio of high expectation shares

John Rosier reviews the lessons learnt in 2018 and explains why he is comfortable starting the new year fully invested

John Rosier is taking a sanguine view of market gyrations, using deratings to work for, rather than against, him

The rising oil price has helped John Rosier's portfolio recover after a difficult start to the year

John Rosier turns to a few simple rules to create a new 20-stock portfolio he hopes will successfully capture their upwards rerating

It's difficult to ignore the powerful factors driving the world towards a robotics future. John Rosier is increasing his exposure to this next big phase in technological change

It pays to react quickly and firmly to early warning signs, says John Rosier

John Rosier discards a sizeable Europe holding in favour of an attractively priced UK medical specialist